3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Ovarian Neoplasms
3
Neoplasm Metastasis
3
Fallopian Tube Neoplasms
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Peritoneal Neoplasms
1
Neoplasms
1
Melanoma
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Limited Stage Small Cell Lung Cancer
1
Hepatic Encephalopathy
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Carboplatin
13
Paclitaxel
8
Bevacizumab
7
Gemcitabine
4
130-nm albumin-bound paclitaxel
4
liposomal doxorubicin
3
relacorilant
2
pembrolizumab
2
nintedanib
2
epothilone B
2
Drug Therapy
2
Albumin-Bound Paclitaxel
2
volociximab
1
tremelimumab
1
phenoxodiol
1
oregovomab
1
olaparib
1
lanreotide
1
farletuzumab
1
enzastaurin
1
durvalumab
1
cc-486
1
catumaxomab
1
atezolizumab
1
Trastuzumab
1
Trabectedin
1
Topotecan
1
Saline Solution
1
Oxaliplatin
1
Octreotide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Peritoneal Neoplasms
×
Glucose
×
Clear all
NCT03740165
2026-05-04
KEYLYNK-001
Merck Sharp & Dohme LLC
Phase 3
Completed
1,367 enrolled
29 charts